NCT00455572 - Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2007

Primary Completion Date

August 4, 2013

Study Completion Date

August 8, 2013

Conditions

Lung Cancer, Non-Small Cell

Interventions

BIOLOGICAL

Immunotherapeutic GSK1572932A

Intramuscular injection, 8 doses

DRUG

Cisplatin (CDDP)

Four cycles with doses based on patient's body surface area, intravenous administration

DRUG

Vinorelbine

Four cycles with doses based on patient's body surface area , intravenous administration

PROCEDURE

Radiotherapy

Regimen will be based upon the site's own standard procedures

Trial Locations (26)

3000

GSK Investigational Site, Leuven

3600

GSK Investigational Site, Genk

4000

GSK Investigational Site, Liège

16132

GSK Investigational Site, Genoa

20132

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

20246

GSK Investigational Site, Hamburg

22927

GSK Investigational Site, Großhansdorf

33100

GSK Investigational Site, Udine

34295

GSK Investigational Site, Montpellier

44805

GSK Investigational Site, Saint-Herblain

55131

GSK Investigational Site, Mainz

58675

GSK Investigational Site, Hemer

67091

GSK Investigational Site, Strasbourg

69495

GSK Investigational Site, Pierre-Bénite

99437

GSK Investigational Site, Bad Berka

T6G 1Z2

GSK Investigational Site, Edmonton

J4V 2H1

GSK Investigational Site, Greenfield Park

H4J 1C5

GSK Investigational Site, Montreal

06120

GSK Investigational Site, Halle

00152

GSK Investigational Site, Rome

M23 9LT

GSK Investigational Site, Wythenshawe

CH63 4JY

GSK Investigational Site, Bebington, Wirral

SE1 9RT

GSK Investigational Site, London

NG5 1PB

GSK Investigational Site, Nottingham

SO16 6YD

GSK Investigational Site, Southampton